Abstract
NSCLC w/EGFRex19del & MET amp: durable intracranial + systemic response to amivantamab/osimertinib.
MeSH terms
-
Acrylamides*
-
Aniline Compounds*
-
Antibodies, Bispecific*
-
Carcinoma, Non-Small-Cell Lung* / drug therapy
-
Carcinoma, Non-Small-Cell Lung* / genetics
-
Carcinoma, Non-Small-Cell Lung* / pathology
-
ErbB Receptors / genetics
-
Humans
-
Indoles*
-
Lung Neoplasms* / drug therapy
-
Lung Neoplasms* / genetics
-
Lung Neoplasms* / pathology
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use
-
Pyrimidines*
Substances
-
osimertinib
-
amivantamab
-
Protein Kinase Inhibitors
-
ErbB Receptors
-
Acrylamides
-
Antibodies, Bispecific
-
Aniline Compounds
-
Indoles
-
Pyrimidines